UPB Upstream Bio Inc Forecast, Technical & Fundamental Analysis
Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders... Show more
UPB is expected to report earnings to rise 49.33% to -112 cents per share on November 05
Q3'26
Est.
$-1.12
Q1'26
Beat
by $0.10
Q4'25
Beat
by $0.06
The last earnings report on May 13 showed earnings per share of -75 cents, beating the estimate of -85 cents. With 211.48K shares outstanding, the current market capitalization sits at 381.75M.
A.I.dvisor indicates that over the last year, UPB has been loosely correlated with IRON. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if UPB jumps, then IRON could also see price increases.
The Moving Average Convergence Divergence (MACD) for UPB turned positive on August 05, 2026. Looking at past instances where UPB's MACD turned positive, the stock continued to rise in of 20 cases over the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
UPB moved above its 50-day moving average on August 07, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for UPB crossed bullishly above the 50-day moving average on August 12, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 2 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where UPB advanced for three days, in of 96 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 17 cases where UPB's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
The Momentum Indicator moved below the 0 level on August 20, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on UPB as a result. In of 25 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where UPB declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
UPB broke above its upper Bollinger Band on August 07, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for UPB entered a downward trend on August 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.409) is normal, around the industry mean (20.145). P/E Ratio (0.000) is within average values for comparable stocks, (22.992). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.861). Dividend Yield (0.000) settles around the average of (0.018) among similar stocks. P/S Ratio (119.048) is also within normal values, averaging (444.692).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. UPB’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. UPB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock worse than average.
Upstream Bio (UPB) stock Forecast, Price Targets and Analysts Predictions - Tickeron.com
